Dolan Sondhi

Dolan Sondhi

Auto-generated profile, based on publicly available information

Dolan Sondhi

Department of Genetic Medicine, Weill Cornell Medicine, New York, New York, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DSDolan Sondhi
Dolan Sondhi
SKStephen M. Kaminsky
Stephen M. Kaminsky
NHNeil R. Hackett
Neil R. Hackett
OPOdelya E. Pagovich
Odelya E. Pagovich
JRJonathan B. Rosenberg
Jonathan B. Rosenberg
RCRonald G. Crystal
Ronald G. Crystal
Administration of an adeno-associated virus coding for the CLN2 gene into the brain parenchyma slows the progression of CLN2 disease in children.

28 January 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
JDJ.P. Dyke
J.P. Dyke
DSD. Sondhi
D. Sondhi
HVHenning Voss
Henning Voss
KYKaleb Yohay
Kaleb Yohay
CHC. Hollmann
C. Hollmann
DBD. Ballon
D. Ballon
BACKGROUND AND PURPOSE: Late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene. Our hypothesis was that regional analysis of cortical brain degeneration may identify brain regions that are affected earliest and most severely by the disease. MATERIALS AND METHODS: Fifty-two high-resolution 3T MR imaging datasets were prospectively acquired on 38 subjects with CLN2. A retrospective cohort of 52 disease-free children served as a control population. The FreeSurfer software suite was used for calculation of cortical thickness. RESULTS: An increased rate of global cortical thinning in CLN2 versus control subjects was the primary finding in this study. Three distinct patterns were observed across brain regions. In the first, subjects with CLN2 exhibited differing rates of cortical thinning versus age. This was true in 22 and 26 of 34 regions in the left and right hemispheres, respectively, and was also clearly discernable when considering brain lobes as a whole and Brodmann regions. The second pattern exhibited a difference in thickness from healthy controls but with no discernable change with age (9 left hemispheres, 5 right hemispheres). In the third pattern, there was no difference in either the rate of cortical thinning or the mean cortical thickness between groups (3 left hemispheres, 3 right hemispheres). CONCLUSIONS: This study demonstrates that CLN2 causes differential rates of degeneration across the brain. Anatomic and functional regions that degenerate sooner and more severely than others compared with those in healthy controls may offer targets for directed therapies. The information gained may also provide neurobiologic insights regarding the mechanisms underlying disease progression.

1 September 2023 in Human Gene Therapy
Verified
Journal Article
Closed access
BDBishnu P. De
Bishnu P. De
JRJonathan B. Rosenberg
Jonathan B. Rosenberg
NSNithya Selvan
Nithya Selvan
IWIsabelle Wilson
Isabelle Wilson
NYNadir Yusufzai
Nadir Yusufzai
DSDolan Sondhi
Dolan Sondhi
CLN2 disease is a fatal, childhood autosomal recessive disorder caused by mutations in CLN2 gene, encoding tripeptidyl peptidase 1 (TPP-1). Loss of TPP-1 activity leads to accumulation of storage material in lysosomes and resultant neuronal cell death with neurodegeneration. Genotype/phenotype comparisons suggest that the phenotype should be ameliorated with increase of TPP-1 levels to 5-10% of normal with wide central nervous system (CNS) distribution. Our previous clinical study showed that intraparenchymal administration of AAVrh.10hCLN2, an AAV serotype rh.10 encoding human CLN2, slowed but did not stop disease progression, suggesting that this may be insufficient to distribute the therapy throughout the CNS (Sondhi 2020). In this study, we assessed whether the less invasive intracisternal delivery route would be safe and provide a wider distribution of TPP-1. A study was conducted in nonhuman primates (NHP) with intracisternal delivery to cerebral spinal fluid of AAVrh.10hCLN2 [5x1013 genome copies] or PBS. No abnormal behaviors were noted. CNS MRI imaging and clinical chemistry data were all unremarkable. Histopathology of major organs had no abnormal findings attributable to the intervention or the vector except that in 1 out of 2 animals treated with AAVrh.10hCLN2, dorsal root ganglia showed mild-to-moderate mononuclear cell infiltrates and neuronal degeneration. In contrast to our prior NHP study (Sondhi 2012) with intraparenchymal administration where TPP-1 activity was >2X above controls in 30% of treated brains, in the 2 intracisternal treated NHPs, the TPP-1 activity was >2X above controls in 50% and 41% of treated brains, and 52% and 84% of brain had >1000 vector genomes/ug DNA, compared to 0% in the 2 PBS NHP. CSF TPP1 levels in treated animals were 43-62% of normal human levels. Collectively, these data indicate that AAVrh.10hCLN2 delivered by intracisternal route is safe and widely distributes TPP-1 in brain and CSF at levels that are potentially therapeutic.

16 August 2023 in Human Gene Therapy
Verified
Journal Article
Closed access
BDBishnu P. De
Bishnu P. De
SCSara Cram
Sara Cram
HLHyunmi Lee
Hyunmi Lee
JRJonathan B. Rosenberg
Jonathan B. Rosenberg
DSDolan Sondhi
Dolan Sondhi
SKStephen M. Kaminsky
Stephen M. Kaminsky
Efficient production of adeno-associated virus (AAV) vectors is a significant challenge. Human embryonic kidney HEK293T cells are widely used in good manufacturing practice facilities, producing higher yield of AAV vectors for clinical applications than HEK293 through the addition of a constitutive expression of SV40 large T antigen (SV40T), which stimulates Rep expression. However, the theoretical potential for tumorigenic consequences of a clinical AAV product containing residual DNA encoding SV40T, which may inhibit p53 growth suppressive functions is a safety concern. Although the risk is theoretical, to assure a low risk/high confidence of safety for clinical drug development, we have established a sensitive assay for assessment of functional full-length transcription competent SV40T DNA in HEK293T cell-produced AAV vectors. Using HEK293T generated 8, 9, and rh.10 serotype AAV vectors, the presence of SV40T in purified vector was assessed in vitro using quantitative polymerase chain reaction (qPCR) targeting a 129 bp amplicon combined with nested PCR targeting full-length SV40T DNA. Although low levels of the smaller amplicon were present in each AAV serotype, the full-length SV40T was undetectable. No transcription competent full-length SV40T DNA was observed by reverse transcription-quantitative polymerase chain reaction using an in vivo amplification of signal in mouse liver administered (2–10 × 10 10 gc) 129 bp amplicon-positive AAV vectors. As a control for gene transfer, high levels of expressed transgene mRNAs were observed from each serotype AAV vector, yet, SV40T mRNA was undetectable. In vivo assessment of these three liver-tropic AAV serotypes, each with amplicon-positive qPCR SV40T DNA, demonstrated high transgene mRNA expression but no SV40T mRNA, that is, detection of small segments of SV40T DNA in 293T cell produced AAV inappropriately leads to the conclusion of residuals with the potential to express SV40T. This sensitive assay can be used to assess the level, if any, of SV40T antigen contaminating AAV vectors generated by HEK293T cells. ClinicalTrials.gov identifier: NCT03634007; NCT05302271; NCT01414985; NCT01161576.

1 February 2023 in Human Gene Therapy
Verified
Journal Article
Closed access
JRJonathan B. Rosenberg
Jonathan B. Rosenberg
BDBishnu P. De
Bishnu P. De
AGAlessandria Greco
Alessandria Greco
NGNicholas Gorman
Nicholas Gorman
VKVikrum Kooner
Vikrum Kooner
DSDolan Sondhi
Dolan Sondhi
α1-antitrypsin (AAT) deficiency is a common autosomal recessive hereditary disorder, with a high risk for the development of early-onset panacinar emphysema. AAT, produced primarily in the liver, functions to protect the lung from neutrophil protease; with AAT deficiency, unimpeded neutrophil proteases destroy the lung parenchyma. AAT is susceptible to oxidative damage resulting in an inability to inhibit its target proteases, neutrophil elastase, and cathepsin G. The major sites of oxidative modification on the AAT molecule are methionine residues 351 and 358. We have previously demonstrated that an engineered variant of AAT that resists oxidation by modifying both protein surface methionines (M351V and M358L) provides antiprotease protection, despite oxidative stress. In mice, intravenous delivery of the modified AAT(AVL) variant by AAV serotype 8, AAV8hAAT(AVL), primarily to the liver resulted in long-term expression of an AAT that resists oxidative inactivation. In this study, we evaluated the safety of intravenous administration of AAV8hAAT(AVL) in a dose-escalating, blinded, placebo-controlled toxicology study in wild-type mice. The study assessed organ histology and clinical pathology findings of mice, intravenously administered AAV8hAAT(AVL) at three doses (5.0 × 1011, 5.0 × 1012, and 5.0 × 1013 genome copies [gc]/kg), compared to control mice injected intravenously with phosphate-buffered saline. As previously demonstrated, administration of AAV8hAAT(AVL) resulted in dose-dependent expression of high, potentially therapeutic, levels of serum human AAT protein that persist for at least 6 months. Antibodies against the AAV8 capsid were elicited as expected, but there was no antibody detected against the AAT(AVL) protein generated by the AAV8hAAT(AVL) vector. There was no morbidity or mortality observed in the study. The data demonstrate that intravenous administration of AAV8hAAT(AVL) is safe with no significant adverse effect attributed to AAV8hAAT(AVL) vector at any dose. This study demonstrates that AAV8hAAT(AVL) has a safety profile consistent with the requirements for proceeding to a clinical study.

1 July 2021 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
KKKyle D. Kovacs
Kyle D. Kovacs
AOAnton Orlin
Anton Orlin
DSDolan Sondhi
Dolan Sondhi
SKStephen M. Kaminsky
Stephen M. Kaminsky
DDDonald J. D'AMico
Donald J. D'AMico
SKSzilárd Kiss
Szilárd Kiss
Purpose: CLN2-associated disease is a hereditary, fatal lysosomal storage disorder characterized by progressive brain and retinal deterioration. Here, we characterize the inner and outer retinal degeneration using automated segmentation software in optical coherence tomography scans, providing an objective, quantifiable metric for monitoring subtle changes previously identified with a validated disease classification scale (the Weill Cornell Batten Scale). Methods: This study is a retrospective, single-center cohort review of images from examinations under anesthesia in treatment-naïve patients with CLN2-associated disease. Automated segmentation software was used to delineate retinal nerve fiber, ganglion cell layer (GCL), and outer nuclear layer (ONL) thickness measurements in the fovea, parafovea, and perifovea based on age groups (months): 30 to 38, 39 to 45, 46 to 52, 53 to 59, 60 to 66, and 67 or older. Results: Twenty-seven eyes from 14 patients were included, with 8 serial images yielding 36 interpretable optical coherence tomography scans. There was a significant difference in parafoveal ONL thickness between 39 to 45 and 46 to 52 months of age (P = 0.032) not seen in other regions or retinal layers. Perifoveal ONL demonstrated a difference in thickness between the 60 to 66 and greater than 67 months age cohorts (P = 0.047). There was strong symmetry between eyes, and high segmentation repeatability. Conclusions: Parafoveal ONL thickness represents a sensitive, early age indicator of CLN2-associated degeneration. Outer retinal degeneration is apparent at younger ages than inner retinal changes though in treatment-naïve patients all retinal layers showed significant differences between 60 to 66 and more than 67 months of age. Translational Relevance: This study establishes sensitive, quantitative biomarkers for assessing retinal degeneration in a large cohort natural history study in anticipation of future clinical trials.